April 4, 2016 / 10:27 AM / in 2 years

BRIEF-Amgen Canada - announces new study results of Repatha in statin-intolerant patients

April 4 (Reuters) - Amgen Canada

* New detailed data from phase 3 gauss-3 trial evaluating repatha in patients with high cholesterol who cannot tolerate statins

* Repatha shown to significantly reduce LDLC-C by about 55 percent after 24 weeks compared to ezetimibe Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below